Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Diabetes
•
Gastroenterology
•
Neurology
•
Autonomic Neurology
•
Endocrinology
•
Neuro-Gastroenterology
•
Gastrointestinal Functional & Motility Disorders
•
Primary Care
Do 5HT4 agonists such as Metoclopramide actually lead to improvement in symptoms for patients with diabetes related gastroparesis?
Related Questions
What is the optimal BP target for patients with diabetes and hypertension to reduce their risk of MI/stroke?
When and how should we be stopping GLP-1 Receptor Agonist/Dual Agonist therapy?
Do you recommend routinely monitoring pancreatic markers such as amylase and lipase while receiving GLP1 R agonist or dual agonist therapies to determine their risk of pancreatitis?
How do you counsel patients on the use of compounded weight loss medications?
Do you recommend the use of SGLT2 inhibitors to reduce the risk of liver cirrhosis in patients with Type 2 diabetes mellitus?
Can rapid weight loss following GLP1 R agonist therapy lead to postprandial hypoglycemia and if so, what are the treatment options outside of dietary modifications?
Do you routinely check vitamin K levels in post-bariatric surgery patients?
Is there a role for use of GLP1 R agonist or dual agonist therapy for management of post bariatric hypoglycemia and dumping syndrome?
What is your approach to addressing severe dawn phenomenon in your patients with diabetes?
Does oral semaglutide provide similar cardiovascular risk reduction benefits as injectable semaglutide?
